(Q56883123)

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Global burden of hypertension: analysis of worldwide data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

From "prehypertension" to hypertension? Additional evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Impact of high-normal blood pressure on the risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

The impact of ethnicity on response to antihypertensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Angiotensin receptor blockers: evidence for preserving target organs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Novel drugs targeting hypertension: renin inhibitors and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Renin, prorenin and the putative (pro)renin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Analysis of structure-activity relationships in renin substrate analogue inhibitory peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Effects of a specific and long-acting renin inhibitor in the marmoset

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Inhibitors of renin as potential therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

A study of the renin inhibitor H142 in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Pharmacology of renin inhibitors and their application to the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Cloning and sequence analysis of cDNA for human renin precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Three-dimensional structure, specificity and catalytic mechanism of renin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

The crystal structures of recombinant glycosylated human renin alone and in complex with a transition state analog inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Structure-based drug design and the discovery of aliskiren (Tekturna): perseverance and creativity to overcome a R&D; pipeline challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

X-ray analyses of peptide-inhibitor complexes define the structural basis of specificity for human and mouse renins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Structure-based design of aliskiren, a novel orally effective renin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Direct Renin inhibition with aliskiren in obese patients with arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417

21 January 2018

Oral renin inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.417